TACC1 Antibodies

Transforming acidic coiled-coil-containing protein 1 (TACC1)

Likely involved in the procedures that promote cell division before the formation of differentiated tissues. .

Gene Information

Human
Gene Name:	TACC1
Uniprot:	O75410
Entrez:	6867

Family

Belongs to:
TACC family

Alternative Names

DKFZp686K18126; FLJ42304; Ga55; Gastric cancer antigen Ga55; KIAA1103; taxin 1; taxin-1; transforming acidic coiled-coil-containing protein 1; transforming, acidic coiled-coil containing protein 1

Molecular Weight

Mass (kDA):
87.794 kDA

Genomic Context

Human
Location:	8p11.22
Sequence:	8; NC_000008.11 (38728205..38853028)

Tissue Specificity

Isoform 1, isoform 3 and isoform 5 are ubiquitous. Isoform 2 is strongly expressed in the brain, weakly detectable in lung and colon, and overexpressed in gastric cancer. Isoform 4 is not detected in normal tissues, but strong expression was found in gastric cancer tissues. Down-regulated in a subset of cases of breast cancer.

Subcellular Localizations

Cytoplasm. Nucleus. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Midbody. Nucleus during interphase. Weakly concentrated at centrosomes during mitosis and colocalizes with AURKC at the midbody during cytokinesis.; [Isoform 5]: Membrane; Lipid-anchor.; [Isoform 10]: Cytoplasm.

Diseases

• Malignant Neoplasms
• Neoplasms
• Malignant Neoplasm Of Breast
• Cell Transformation, Neoplastic
• Mammary Neoplasms
• Carcinoma
• Ovarian Neoplasm
• Adenocarcinoma
• Multiple Myeloma
• Malignant Neoplasm Of Stomach
• Stomach Neoplasms
• Glioma
• Aneuploidy

• Malignant Paraganglionic Neoplasm
• Metaplastic Cell Transformation
• Carcinogenesis
• Malignant Neoplasm Of Ovary
• Cystadenocarcinoma, Serous
• Melanoma
• Malignant Tumor Of Colon

Interacting Proteins

• AURKB
• BTRC
• CKAP5
• HTT
• LSM7

• MEMO1
• SH2D4A
• SNRPG
• STX5
• TDRD7

• THAP12
• YEATS4

Pathways

• Cell Division
• Cell Cycle
• Cytokinesis
• Mitosis
• Localization
• Translation
• Cell Growth
• M Phase
• Anaphase
• Regulation Of Mitosis
• Oncogenesis
• Cell Proliferation
• Methylation

• Mammary Gland Involution
• Chromosome Segregation
• Mrna Processing
• Interphase
• Chromosome Condensation
• Blood Vessel Development
• Dna Repair

PTMs

• Phosphorylation

• Methylation

• Ubiquitination

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/TACC1

Best Uses Of The TACC1 Marker

Anti-TACC1 antibodies can be very useful in any TACC1-related assay, in a clinical or biological setting. Boster Bio offers anti TACC1 antibodies which are widely used for biological assays. This antibody can be used in the following areas: Clinical Assays, Special Samples, Applications. Scientists worldwide can apply for product credits through this program.

Anti-TACC1 antibodies are widely used for biological assays

There are many suppliers that offer anti-TACC1 antibodies for biological assays. The antibody is made to recognize TACC1 ("transforming acidic coil-coil protein), which is a common gene associated with gastric carcinoma. This protein is also known as Ga55, taxin-1, or gastric cancer antigen. TACC1 is also available in several orthologs.

TACC1 is an important protein that modulates transcriptional activity through nuclear receptors. Immunoblotting was used for the determination of protein levels in HEK-293F-cells. Control cells were treated using a non-targeting siRNA as well as a non-targeting, siRNA. Anti-TACC1 siRNA was used for treatment of cells with 10-7M T3 and all trans RA.

TACC1 expression patterns have been found to differ between human tissues based on molecular analysis. TACC1 function is affected by mRNA splicing patterns in cancer cells. TACC1 protein expression that is full-length results in increased ERK/PKB phosphorylation. Full-length TACC1 proteins can play a role in autophagy regulation by cooperating with AKT/mTOR.

TACC1 is also found in yeast cells and mammalian cells. It is believed that it is involved in transcription of ER target genes. TACC1 overexpression may play a significant role in oncogenic development, according to some reports. TACC1 alterations have been found in breast cancer, which is regulated via estrogen receptors. TACC1 was first described in the study of amplicon that were associated with ER positive lobular carcinomas.

TACC1 can interact with the nuclear receptacle RARa in F9 cell. TACC1 was detected in the nuclear chromatin enriched fraction. Flag-RARa-overexpression cells were used to perform co-immunoprecipitation assays. Flag-RARa-overexpression of F9 cells was also used to explore the nuclear interactions of TACC1 with the nuclear receptor. Flag-RARa overexpression was only five fold greater than endogenous levels of RARa protein. The absence or cross-contamination was confirmed by superna's ratios of Flag-RARa protein in TACC1 and Flag-RARa protein in superna.

TACC1 is part of the FHL protein group. Its function is not understood yet. However, the Drosophila TACC Protein associates with microtubules (centrosomes) and is known to be a part of the Drosophila TACC protein. The human TACC1 protein encodes a multiPDZ domain protein. It contains 13 PDZ repeats.

Clinical applications

The TACC1 gene encodes the cytokine and its expression levels correspond with the type or cancer. Specifically, a gene called TACC1 regulates cell proliferation and inhibits apoptosis. It is not known if this gene is involved in oral carcinogenesis. As new research is conducted, clinical applications will continue to be made of the TACC1 mark.

TACC1 is closely connected to transcription, Translation, and Centrosome Dynamics. TACC1 dysregulation is associated with many types and types of cancers. There are several variants TACC1 that play different roles in cancer biology. TACC1v25 expression was reduced in HNSCC, while full-length TACC1 increased expression induced inhibition of autophagy and proliferation.

TACC1 is one among many available tumor markers in routine clinical laboratory. In asymptomatic men, it may be useful in detecting prostate cancer. It can also be used to screen for breast cancer in women. Women may also benefit from a prostate specific antigen test. Although the FDA has not approved this test for use in this way, it is a promising start towards early detection of breast Cancer.

TUNEL was used to measure TACC1 levels in hepatocellular tumour cells. Lenti-TACC1v25-Cal27/-Fadu cells were also more likely to have increased levels of autophagosomes. TACC1v25 cells also showed an increased level of autophagic markers including LC3II/I, Beclin-1, and autophagic protein (Atg1) as detected by western blot analysis. Red indicates cells that are in apoptosis.

A TACC1-FGFR1 fusion can also be associated with low-grade biology. This mutation is especially common in extra ventricular neuralgia, a rare primary brain cancer. Its histological morphological characteristics and morphology are similar to those of central neurocytomas making it difficult for accurate diagnosis. Recent research has revealed that the TACC1 gene is a distinct epigenetic category.

Targeted silencing TACC3 suppresses CCA-related tumorigenicity

TACC3 expression in human RCC cells suppresses cancerigenicity and induces cell proliferation. This downregulation can inhibit EMT-related genes which are essential for cancer progression. Targeted silencing TACC3 reduces CCA tumorigenicity through suppression of tumor-promoting PI3K/Akt signaling.

TACC3 proteins make complexes and interact with histone acetyltransferases. They are directly involved in transcriptional regulation. TACC3 works with MBD2 by binding to methylated promotors to activate MBD2-mediated transcriptional repression. Its role is unknown in RCC. To understand the role of TACC3 in tumorigenesis, targeted silencing is used to inhibit tumor progression by inducing its expression in cancer cell cells.

The researchers used shRNA-lentiviruses in order to transfect Caki-1 with TACC3 -shRNA or nontargeting SHRNA. The lentiviruses inhibited the expression of Hsa_circ_0009035 and RACGAP1 mRNA but did not suppress the expression of hsa_circ_0009035. Knockdown Hsa_circ_0009035 caused cell proliferation and invasion to be suppressed, but not cell death.

Researchers also examined the effects of forced expression of miR-889-3p in two human cell line models on MMP3 or PCNA. This compound suppressed HOXB7 expression and PCNA expression. Targeted silencing TACC3 prevented MMP3 expression from tumor-bearing CC cells. However, researchers could not determine how to achieve this result with human tumors.

These promising findings will offer new insights into how to treat this disease. These findings could open the door to new treatments. Targeted silencing TACC3 reduces CCA tumorigenicity and induces GAPDH expression. So, what's next? Researchers want to know more about the complex disease.

Boster Bio sells anti-TACC1 immunoglobulins

Anti-TACC1 antibody is a great choice to detect this protein. It has been linked to breast cancer. This gene is located near FGFR1 (chromosome 8), and it contains three transcript variants encoding distinct isoforms. As with most other antibodies, Boster Bio's TACC1 antibodies are validated with known positive and negative samples.

BoSTER has high-affinity monoclonal anti TACC1 monoclonal antibodies. BoSTER has extensive validation on WB and IHC as well as ELISA and Western Blotting. Boster antibodies are highly effective in research due to their high affinity. Boster's antibody range has over 12,000 different antibodies that have been validated against known amounts of recombinant proteins and untransfected cell lines.